Published in J Clin Oncol on August 01, 1999
18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer. | NCT00414934
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2009) 1.87
Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging (2008) 1.54
The isotope bone scan: we can do better. Eur J Nucl Med Mol Imaging (2013) 1.39
Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol (2010) 1.25
Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.11
Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging (2013) 1.08
Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? Adv Urol (2011) 1.05
Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy. Eur Radiol (2011) 1.05
18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res (2011) 1.03
Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging (2004) 1.02
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Assessment of successful incorporation of cages after cervical or lumbar intercorporal fusion with [(18)F]fluoride positron-emission tomography/computed tomography. Eur Spine J (2010) 0.95
MRI and (18)FDG-PET in the assessment of bone marrow infiltration of the spine in cancer patients. Eur Spine J (2007) 0.90
Clinical Usefulness of (18)F-fluoride Bone PET. Nucl Med Mol Imaging (2010) 0.88
PET and PET/CT imaging of skeletal metastases. Cancer Imaging (2010) 0.88
A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol (2010) 0.87
Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol (2014) 0.87
Therapeutic impact of [(18)F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain. Skeletal Radiol (2010) 0.86
(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biol Ther (2008) 0.85
F-18 fluoro-deoxy-glucose and F-18 sodium fluoride cocktail PET/CT scan in patients with breast cancer having equivocal bone SPECT/CT. Indian J Nucl Med (2014) 0.83
Molecular imaging in myeloma precursor disease. Semin Hematol (2011) 0.83
Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging (2015) 0.82
PET/CT and breast cancer. Cancer Imaging (2010) 0.79
Bone positron emission tomography with or without CT is more accurate than bone scan for detection of bone metastasis. Korean J Radiol (2013) 0.79
Comparison of standardized uptake values measured on F-NaF PET/CT scans using three different tube current intensities. Radiol Bras (2015) 0.78
Receiver operating characteristic (ROC) curve for classification of (18)F-NaF uptake on PET/CT. Radiol Bras (2016) 0.78
Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2004) 0.78
Advances in drug design of radiometal-based imaging agents for bone disorders. Int J Mol Imaging (2011) 0.77
Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging. PET Clin (2009) 0.77
Guidelines for paediatric bone scanning with 99mTc-labelled radiopharmaceuticals and 18F-fluoride. Eur J Nucl Med Mol Imaging (2010) 0.77
Evaluation of bone-seeking novel radiotracer (68)Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast. Eur J Nucl Med Mol Imaging (2016) 0.77
miR-301a expression: A prognostic marker for prostate cancer. Urol Oncol (2016) 0.76
The role of 18F-NaF PET/CT in metastatic bone disease. J Bone Oncol (2015) 0.75
Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions. World J Radiol (2016) 0.75
Feasibility of treating irradiated bone with intramedullary delivered autologous mesenchymal stem cells. J Biomed Biotechnol (2011) 0.75
18F-Labeled NaF PET-CT in Detection of Bone Metastases in Patients With Preoperative Lung Cancer. Medicine (Baltimore) (2016) 0.75
Skeletal metastases: what is the future role for nuclear medicine? Eur J Nucl Med Mol Imaging (2009) 0.75
Complementary findings on (18)F-FDG PET/CT and (18)F-NaF PET/CT in a patient with Erdheim-Chester disease. Radiol Bras (2017) 0.75
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res (2000) 2.83
Human ovarian tissue cryopreservation: quality of follicles as a criteria of effectiveness. Reprod Biomed Online (2010) 2.46
Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med (2000) 2.15
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology (2010) 1.84
p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet (1995) 1.84
Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol (2002) 1.72
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res (2001) 1.59
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol (2005) 1.58
Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol (2000) 1.56
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med (1999) 1.53
Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med (2001) 1.47
Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat (2000) 1.45
p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol (1999) 1.45
Human ovarian tissue vitrification versus conventional freezing: morphological, endocrinological, and molecular biological evaluation. Reproduction (2009) 1.42
Catabolism of 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) by isolated rat hearts. Eur J Nucl Med (1990) 1.39
[Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer]. Geburtshilfe Frauenheilkd (1993) 1.39
[Diabetes screening in pregnant patients with different risk factors. Benefits, therapeutic success, consequences]. Z Geburtshilfe Neonatol (1996) 1.39
[Building the future together]. Nuklearmedizin (2012) 1.39
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med (2001) 1.36
Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin (2011) 1.36
Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med (1999) 1.35
Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci (1991) 1.35
Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol (2009) 1.33
Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol (2002) 1.32
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer (2001) 1.30
Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging (2002) 1.28
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology (1995) 1.24
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics (2001) 1.23
Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut (1995) 1.23
FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med (1998) 1.22
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med (2001) 1.22
New approach in the diagnosis of and therapy for Hughes-Stovin syndrome. AJR Am J Roentgenol (1996) 1.22
Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology (1998) 1.21
Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection (2001) 1.21
Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg (2000) 1.20
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol (1998) 1.19
Hereditary defect of hepatobiliary cysteinyl leukotriene elimination in mutant rats with defective hepatic anion excretion. Hepatology (1987) 1.19
Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med (1997) 1.19
In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport (2000) 1.18
Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol (2001) 1.17
Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster. J Clin Invest (1991) 1.17
Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res (2008) 1.17
Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med (2006) 1.15
Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin (2003) 1.14
Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today (1994) 1.14
Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat (2013) 1.14
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat (2010) 1.13
p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res (1998) 1.13
Emptying of the gastric substitute after total gastrectomy. Jejunal interposition versus Roux-y esophagojejunostomy. Ann Surg (1989) 1.12
Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol (1998) 1.11
Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas (2000) 1.10
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol (2013) 1.09
Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology (1998) 1.09